Analyst Research

Report Title Price
Prestige Brands Holdings Inc (PBH) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy
Thomson Reuters Stock Report - PRESTIGE BRANDS HOLDINGS, INCORPORATION (PBH-N)
Provider: Thomson Reuters Stock Report
$25.00
Buy
ValuEngine Detailed Valuation Report for PBH
Provider: ValuEngine, Inc.
$127.00
Buy
ValuEngine - Toronto Quantitative Stock Report for PBH
Provider: ValuEngine, Inc.
$127.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Prestige Brands Holdings Inc Reaffirms FY 2013 EPS Guidance


Thursday, 17 May 2012 05:35am EDT 

Prestige Brands Holdings Inc announced that it is confident in guidance previously provided for fiscal 2013, anticipating diluted adjusted earnings per share to be in the range of $1.22 to $1.32. According to I/B/E/S Estimates, were expecting the Company to report EPS of $1.27 for fiscal 2013. 

Latest Developments for Prestige Brands Holdings Inc

Latest Key Developments in Pharmaceuticals

Company Quote

Prestige Brands Holdings Inc
(PBH.N)
28.4
0.15 +0.53%
11:33am EDT